Sugi Predict

Sugi Predict / Compounds / SCHEMBL1949502

SCHEMBL1949502

SCHEMBL1949502

O=Cc1cc(O)cc(F)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 1/20 0.55
▸ CA1 P00915 1/20 0.55
▸ CA9 Q16790 1/20 0.55
▸ HCAR1 Q9BXC0 1/20 0.45
▸ PTGS1 P23219 3/20 0.44
▸ PTGS2 P35354 3/20 0.44
▸ ERN1 O75460 1/20 0.43
▸ ALDH5A1 P51649 2/20 0.42
▸ ABAT P80404 2/20 0.42
▸ LCK P06239 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ BACE1 P56817 1/20 0.38
▸ MAOA P21397 2/20 0.36
▸ MAOB P27338 2/20 0.36
▸ ALDH1A1 P00352 2/20 0.35
▸ AOX1 Q06278 1/20 0.35
▸ TRIM24 O15164 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30134352 1.00 CA12 (0.55) CA12CA1CA9HCAR1PTGS1
SCHEMBL37131 0.82 LCK (0.58) CA12CA1CA9PTGS1PTGS2
SCHEMBL9261197 0.82 LCK (0.58) CA12CA1CA9PTGS1PTGS2
SCHEMBL4575600 0.82 ALDH5A1 (0.52) CA12CA1CA9PTGS1PTGS2
SCHEMBL6854243 0.82 ERN1 (0.41) PTGS1PTGS2ERN1KDM4ERAB9A
SCHEMBL96269 0.82 ERN1 (0.41) CA12CA1CA9PTGS1PTGS2
Potassium SCHEMBL31540630 0.79 LCK (0.55) CA12CA1CA9PTGS1PTGS2
Ammonia Solution, Strong SCHEMBL13735346 0.79 ERN1 (0.39) CA12CA1CA9PTGS1PTGS2
SCHEMBL16951827 0.78 CA12 (0.57) CA12CA1CA9HCAR1PTGS1
Phloroglucinol SCHEMBL28580013 0.76 ALDH5A1 (0.52) CA12CA1CA9PTGS1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4648762-A2 PPARG MODULATORS University of Florida Research Foundation, Incorporated (US) 2025-11-19 — — EP disclosed
WO-2025107036-A1 DUAL INHIBITORS OF AMINE OXIDASES AND PEROXIDASES, AND USES THEREOF SYNTARA LIMITED (AU) 2025-05-30 — — WO disclosed
CN-118359638-A Compound serving as RET kinase inhibitor and preparation method and application thereof 苏州朗睿生物医药有限公司 2024-07-19 — — CN disclosed
WO-2024151519-A2 PPARG MODULATORS UNIVERSITY OF FLORIDA RESEARCH FOUNDATIN, INCORPORATED (US) 2024-07-18 — — WO disclosed
WO-2024151519-A2 PPARG MODULATORS UNIVERSITY OF FLORIDA RESEARCH FOUNDATIN, INCORPORATED (US) 2024-07-18 — — WO disclosed
US-12024531-B2 Immunoproteasome inhibitors PRINCIPIA BIOPHARMA INC. (US) 2024-07-02 — — US disclosed
US-20240122876-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS NATIONAL SCIENCE FOUNDATION 2024-04-18 — — US disclosed
US-20240018182-A1 GLUCOCORTICOID RECEPTOR AGONISTS ELI LILLY AND COMPANY 2024-01-18 — — US disclosed
CN-111491939-B Immunoproteasome inhibitors 普林斯匹亚生物制药公司 2023-12-26 — — CN disclosed
US-11787834-B2 Glucocorticoid receptor agonists ELI LILLY AND COMPANY (US) 2023-10-17 — — US disclosed
EP-2507237-A1 IMIDAZOQUINOLINES WHICH ACT VIA TOLL - LIKE RECEPTORS (TLR) Dainippon Sumitomo Pharma Co., Ltd. (JP) 2012-10-10 — — EP disclosed
US-20120251581-A1 Novel Compound and Methods for its Production Abliva Ab (SE) 2012-10-04 — — US disclosed
US-20120251581-A1 Novel Compound and Methods for its Production Abliva Ab (SE) 2012-10-04 — — US disclosed
WO-2012131371-A1 MACROCYCLIC COMPOUND AND METHODS FOR ITS PRODUCTION BIOTICA TECHNOLOGY LIMITED (GB) 2012-10-04 — — WO disclosed
WO-2012131377-A1 MACROCYCLIC COMPOUNDS AND METHODS FOR THEIR PRODUCTION BIOTICA TECHNOLOGY LIMITED (GB) 2012-10-04 — — WO disclosed
WO-2012085553-A1 SANGLIFEHRIN DERIVATIVES AND METHODS FOR THEIR PRODUCTION BIOTICA TECHNOLOGY LIMITED (GB) 2012-06-28 — — WO disclosed
US-20120149682-A1 HETEROCYCLIC-SUBSTITUTED PYRROLOPYRIDINES AND PYRROLOPYRIMIDINES AS JAK INHIBITORS INCYTE CORPORATION 2012-06-14 — — US disclosed
WO-2012068440-A1 HETEROCYCLIC-SUBSTITUTED PYRROLOPYRIDINES AND PYRROLOPYRIMIDINES AS JAK INHIBITORS INCYTE CORPORATION (US) 2012-05-24 — — WO disclosed
WO-2011068233-A1 IMIDAZOQUINOLINES WHICH ACT VIA TOLL - LIKE RECEPTORS (TLR) DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-06-09 — — WO disclosed
US-20110136801-A1 Novel Compounds DAINIPPON SUMITOMO PHARMA CO. LTD. (JP) 2011-06-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149682-A1 HETEROCYCLIC-SUBSTITUTED PYRROLOPYRIDINES AND PYRROLOPYRIMIDINES AS JAK INHIBITORS JAK2, JAK1, JAK3 CA12 4821/4885CA1 4608/4885CA9 3605/4885
US-20240018182-A1 GLUCOCORTICOID RECEPTOR AGONISTS NR3C1, NR3C2, MC2R CA12 3475/4885CA1 3448/4885CA9 3847/4885
US-20240122876-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS UACA, CRYZ, MAPT CA12 155/4885CA1 1005/4885CA9 631/4885
US-20110136801-A1 Novel Compounds C1R, RB1, CNKSR1 CA12 1985/4885CA1 1880/4885CA9 1090/4885
US-11787834-B2 Glucocorticoid receptor agonists NR3C1, NR3C2, MC2R CA12 3475/4885CA1 3448/4885CA9 3847/4885
US-12024531-B2 Immunoproteasome inhibitors PSMC2, PSMB7, PSMB2 CA12 2297/4885CA1 1965/4885CA9 2406/4885
US-20120251581-A1 Novel Compound and Methods for its Production EIF2AK2, HAVCR2, CYP51A1 CA12 1499/4885CA1 3600/4885CA9 2049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.